Rebecca Tweardy
Medical · Lexington, KYNPI 1144390907
Payments from drug & device makers
Across 133 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$553
- Mannkind Corporation$451
- Abbott$176
- AbbVie$140
- AstraZeneca$135
- Lilly USA, LLC$134
- plus $929 from 18 others
What the payments were for
- Food & beverage$2,507100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 14 | $553 |
| Mannkind Corporation | 31 | $451 |
| Abbott | 11 | $176 |
| AbbVie | 9 | $140 |
| AstraZeneca | 9 | $135 |
| Lilly USA, LLC | 8 | $134 |
| Insulet Corporation | 6 | $128 |
| Antares Pharma, Inc. | 3 | $102 |
| Bayer | 6 | $93 |
| Boehringer Ingelheim | 5 | $85 |
| Novo Nordisk | 5 | $81 |
| Sanofi-aventis U.S. LLC | 6 | $79 |
| Amgen(2 entities) | 5 | $74 |
| Medtronic | 2 | $46 |
| Corcept Therapeutics | 3 | $46 |
| BETA Bionics, Inc. | 1 | $39 |
| Amryt Pharma Holdings Ltd | 2 | $32 |
| Halozyme Inc | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Pfizer | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| BD | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $12 |
How this compares
$2,518 in reported general payments places this provider in the 65th percentile of 222 medical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 192 | $315,994 |
| MounjaroTirzepatide | 149 | $177,770 |
| JardianceEmpagliflozin | 120 | $135,590 |
| TrulicityDulaglutide | 67 | $119,578 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $85,316 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $82,945 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $77,751 |
| FarxigaDapagliflozin Propanediol | 56 | $71,921 |
| JanuviaSitagliptin Phosphate | 53 | $49,973 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $43,202 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $42,615 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $30,883 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $24,281 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 126 | $23,776 |
| InvokanaCanagliflozin | 24 | $23,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $81 | $325,121225 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $134 | $313,765282 claims |
| Boehringer IngelheimJardiance | $85 | $135,590120 claims |
| AstraZenecaFarxiga | $135 | $71,92156 claims |
| AbbVieSynthroid | $140 | $5,75886 claims |
| Sanofi-aventis U.S. LLCLantus | $79 | $4,16917 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $3,422287 claims |
| IBSA Pharma Inc.Tirosint | $12 | $3,11913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 222 medical providers in Kentucky.
Other medical in Lexington
- Chasity HesterLexington$16K
- Allison ScottLexington$8K
- Micah BuckelLexington$7K
- Rebecca KraftickLexington$6K
- Anna SchaeferLexington$6K
- Christen MontgomeryLexington$5K
- Tracy JohnsonLexington$5K
- Sarah GrimmLexington$5K
- Whitney WhitakerLexington$4K
- Hannah BurfordLexington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.